Overview
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.
Indication
For the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
Associated Conditions
- Hypertension
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2009/09/28 | Phase 1 | Completed | |||
2009/09/18 | Phase 1 | Completed | |||
2006/04/06 | Phase 4 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Physicians Total Care, Inc. | 54868-5931 | ORAL | 40 mg in 1 1 | 5/22/2012 | |
| Mylan Pharmaceuticals Inc. | 0378-2099 | ORAL | 34 mg in 1 1 | 9/30/2022 | |
| Physicians Total Care, Inc. | 54868-5993 | ORAL | 25.5 mg in 1 1 | 6/8/2012 | |
| Covis Pharma US, Inc | 70515-503 | ORAL | 34 mg in 1 1 | 7/26/2017 | |
| Covis Pharma US, Inc | 70515-500 | ORAL | 8.5 mg in 1 1 | 7/26/2017 | |
| Covis Pharma US, Inc | 70515-501 | ORAL | 17 mg in 1 1 | 7/26/2017 | |
| United Research Laboratories, Inc. | 0677-1978 | ORAL | 8.5 mg in 1 1 | 9/1/2009 | |
| United Research Laboratories, Inc. | 0677-1981 | ORAL | 34 mg in 1 1 | 9/1/2009 | |
| Mylan Pharmaceuticals Inc. | 0378-2224 | ORAL | 40 mg in 1 1 | 6/28/2017 | |
| Mylan Pharmaceuticals Inc. | 0378-2097 | ORAL | 17 mg in 1 1 | 9/30/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| SYSCOR 10 MG COMPRIMIDOS RECUBIERTOS CON PELICULA | Bayer Hispania S.L. | 59480 | COMPRIMIDO RECUBIERTO CON PELÍCULA | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Not Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.